Recent Quotes
My Watchlist
Indicators
Cabling Market Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Ligand Pharmaceuticals Incorporated - Common Stock (NQ:LGND)

135.23 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 30, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Ligand Pharmaceuticals Incorporated - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
Pelthos, Ligand Gain After Launch Of First Prescription-At-Home Treatment For Water Warts
The launch triggered a $5 million milestone payment to Ligand, which also holds a 56% stake in Pelthos and is eligible for royalties and additional commercial milestones. 
Via Stocktwits
Topics Government
Pelthos Therapeutics Launches First At-Home Prescription Gel For Highly Contagious Skin Disease
Pelthos launches Zelsuvmi, the first FDA-approved at-home prescription gel for molluscum, shown to clear lesions in as little as two weeks. 
Via Benzinga
Verona Pharma, Rhythm Pharmaceuticals, AES And Other Big Stocks Moving Higher On Wednesday
 
Via Benzinga
Earnings Scheduled For May 8, 2025
 
Via Benzinga
Gold Falls Over 1%; D.R. Horton Posts Downbeat Earnings
 
Via Benzinga
Earnings Scheduled For February 27, 2025
 
Via Benzinga
Demystifying Ligand Pharmaceuticals: Insights From 10 Analyst Reviews
 
Via Benzinga
A Closer Look at 7 Analyst Recommendations For Ligand Pharmaceuticals
 
Via Benzinga
Channel Therapeutics Stock Soars On Announcement Of Subsidiary’s Merger With Ligand Pharma Units: Retail’s Elated
Under the agreement, Ligand’s wholly owned subsidiaries, Pelthos Therapeutics Inc. and LNHC, Inc. will combine with CHRO Merger Sub Inc., a wholly-owned subsidiary of Channel. 
Via Stocktwits
Dow Falls Over 1%; US Initial Jobless Claims Decline
 
Via Benzinga
Topics Stocks
EXCLUSIVE: Ligand Subsidiary Pelthos Therapeutics To Combine with Channel Therapeutics Creating Pain Medicines Focused Entity
Ligand and Channel Therapeutics to merge in $50 million deal to launch Zelsuvmi for molluscum and advance NaV 1.7 chronic pain programs. 
Via Benzinga
Analyst Sees Big Upside In Ligand's Capital-Efficient Biotech Strategy
Ligand earns Buy rating from Stifel for its royalty-based funding model and biotech partnerships amid strong revenue and earnings growth. 
Via Benzinga
Assessing Ligand Pharmaceuticals: Insights From 7 Financial Analysts
 
Via Benzinga
The Latest Analyst Ratings For Ligand Pharmaceuticals
 
Via Benzinga
Looking Into Ligand Pharmaceuticals's Recent Short Interest
 
Via Benzinga
This Ligand Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
 
Via Benzinga
Ligand to Report Fourth Quarter and Full Year 2024 Financial Results on February 27, 2025
From Ligand Pharmaceuticals Incorporated
Via Business Wire
Ligand to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference
From Ligand Pharmaceuticals Incorporated
Via Business Wire
Biotech Stocks Prepare For Action In 2025. Weight-Loss Drugs, AI And Trump 2.0 Are The Catalysts.
Biotech stocks have seen three years of sideways to down trading. But obesity drugs, AI and Trump 2.0 promise to shake things up. 
Via Investor's Business Daily
Topics Artificial Intelligence Government
Ligand Hosts 2024 Investor and Analyst Day and Introduces 2025 Guidance
From Ligand Pharmaceuticals Incorporated
Via Business Wire
Arcellx And Legend Bio Trade Jabs In Multiple Myeloma. But Only One Pulls Ahead.
The companies held competing events on Sunday to discuss their multiple myeloma treatments. 
Via Investor's Business Daily
Ligand to Present at Stifel 2024 Healthcare Conference
From Ligand Pharmaceuticals Incorporated
Via Business Wire
Ligand Reports Third Quarter 2024 Financial Results and Raises 2024 Guidance
From Ligand Pharmaceuticals Incorporated
Via Business Wire
Ligand to Host Investor and Analyst Day on December 10, 2024 in Boston
From Ligand Pharmaceuticals Incorporated
Via Business Wire
Ligand to Report Third Quarter 2024 Financial Results on November 7, 2024
From Ligand Pharmaceuticals Incorporated
Via Business Wire
Critical Insights From Ligand Pharmaceuticals Analyst Ratings: What You Need To Know
 
Via Benzinga
Palvella Therapeutics Appoints Matthew E. Korenberg as Chief Financial Officer
Mr. Korenberg is a seasoned executive with significant operational and financial leadership experience, including senior roles at Ligand Pharmaceuticals (NASDAQ: LGND) and in healthcare investment... 
From Palvella Therapeutics
Via GlobeNewswire
Ligand Partner Travere Therapeutics Receives Full FDA Approval for FILSPARI® (sparsentan), the Only Non-Immunosuppressive Treatment that Significantly Slows Kidney Function Decline in IgA Nephropathy
From Ligand Pharmaceuticals Incorporated
Via Business Wire
Ligand to Present at H.C. Wainwright 26th Annual Global Investment Conference
From Ligand Pharmaceuticals Incorporated
Via Business Wire
Stock Market Rally Begins After Global Rout; Palantir, Eli Lilly, Fortinet Jump: Weekly Review
After Monday's panicked global sell-off, markets have calmed down. 
Via Investor's Business Daily
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.